New laser zaps painful skin bumps in small trial
NCT ID NCT06801795
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This study tests whether a special 1726nm laser can safely reduce the painful bumps and inflammation caused by hidradenitis suppurativa (HS). Eight adults with mild to moderate HS will receive laser treatment on affected areas like armpits or groin. The main goal is to see if at least half of the bumps disappear without worsening abscesses or draining tunnels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
8 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
Jul 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Female or Male. 2. Fitzpatrick Skin Types I-VI. 3. 18 to 60 years of age. 4. Has a clinical diagnosis of HS (stage 1-2 on the Hurley scale \[Appendix 1\] based on assessment by the investigator). 5. Presence of nodule(s) in the bilateral axillas, inguinal, infra-mammary, thighs, or buttocks within the past 4 weeks 6. Subject must be able to read, speak, and understand English or Spanish and sign the Informed Consent Form. 7. Willing and able to adhere to the treatment and follow-up schedule and pre/post-treatment care instructions. 8. No contraindication to laser therapy. 9. Willing to undergo biopsy at the beginning of study and end of study. 10. Willing to have photographs taken of the treatment area and agree to the use of photographs for presentation, educational or marketing purposes. 11. Agree to not undergo any other procedure(s) or add any new treatment modalities in the treatment area during the study. 12. Willing to use investigator approved skincare topicals and follow investigator approved skincare regimen for the duration of the study. Exclusion Criteria: 1. Has clinically diagnosed HS of severity grade 3 based on assessment by the investigator. 2. Absence of nodule(s) in the bilateral axilla, inguinal, infra-mammary, thighs, or buttocks within the past 4 weeks. 3. Prior treatment to the target area during participation in a clinical trial of another device or drug within 1 month (30 days) prior to study participation. 4. Prior treatment to the target area within 3 months of study participation including chemical peel, dermabrasion, microneedling, radiofrequency treatment, laser or light-based procedures, cryodestruction or chemodestruction, intralesional steroids, photodynamic therapy, or acne surgery. 5. Prior injection of botulinum toxin in the target area within 3 months of study participation and for the duration of the study. 6. Systemic use of retinoid, such as isotretinoin, within 3 months of study participation. 7. Still healing from another treatment in the target area according to investigator's discretion. 8. History of malignant tumors in the target area. 9. Excessive hair that may preclude treatments, photos or accurate HS assessments in the target area (okay if shaved). 10. Pregnant and/or breastfeeding or planning to become pregnant during the study. 11. Suffering from diagnosed coagulation disorders or taking prescription anticoagulation medications. 12. History of diagnosed immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. 13. History of diagnosed connective tissue disease, such as systemic lupus erythematosus or scleroderma. 14. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion. 15. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the target area, unless treatment is conducted following a prophylactic regimen. 16. History of radiation to the target area, currently undergoing treatment for skin cancer in the target area or undergoing systemic chemotherapy for the treatment of cancer. 17. History of diagnosed pigmentary disorders (including vitiligo) in the target area. 18. Excessively tanned in the treatment area or unable/unlikely to refrain from tanning in the target area during the study. 19. History of keloids or hypertrophic scarring 20. Prisoners 21. As per the Investigator's discretion, any physical, mental or medical condition which might make it unsafe for the subject to participate in this study, might interfere with patient's participation in the full study protocol, or might interfere with the diagnosis or assessment of HS.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Weight-Loss drug also calm a painful skin disease?
- Viruses that kill bacteria: a new weapon against superbugs?
- Can an injected drug calm the painful flares of hidradenitis suppurativa?
- Nanobody drug tested against painful skin condition
- Can a mediterranean diet tame hidradenitis suppurativa?
- Can we predict the path of chronic skin disease?